Experienced Entrepreneur, Biochemist, Founder, CEO with a demonstrated history of working in the biotech industry and 14 years of experience (5 years in Senior Management) in preclinical development of compounds to protect neuron in varies neurological diseases. Managed budgets for USD 1 million. In Elixiria, he led a team and discovered new PPAR gamma agonists. Prior to Elixiria, he was a biochemical leader in the Dept. of Anesthesiology, Albert Einstein College of Medicine, where they discovered new compounds for treating Alzheimer’s disease. Before Albert Einstein in 2006, he worked in Columbia Univ. as a research fellow on heart regeneration. Prior to joining Columbia Univ., he worked as a Scientist in Signase Inc. that discovered Src inhibitor for treating colon cancer. In addition, he successfully administered these projects (e.g. staffing, research protections, budget), collaborated with other researchers, and produced over 20 peer-reviewed publications and 2 patents. Holds a PhD. in Biochemistry from the Univ. of Texas – Houston Health Sci. Ctr. / MD Anderson Cancer Ctr.
Director and Professor of Anesthesiology Dept. in the Affiliated Hospital of The Univ. of New Mexico, USA. Associate director of International Society of Pain, Associate editor of Pain Journal, a member of American Pain Society. 36 years’ research experience in pain. Published 10 American patents on pain treatment and 179 peer-reviewed academic papers on pain.
Professor in Department of Anesthesiology, at University of Illinois at Chicago. He His lab study disease progression in mouse models of Alzheimer’s disease (AD) and multiple sclerosis (MS). He has published over 108 peer-reviewed academic papers on AD or MS, and has directed a Phase II clinical of pioglitazone (PPARg agonist just like our compound) on MS. His lab is currently testing our compound ELB00824 in his MS cell and animal model. He will be advising and leading our clinical trial efforts for AD and MS.
Assistant professor in Department of Anesthesiology, at University of Illinois at Chicago, work in the group of Professor of Ophthalmology, Steven Roth. KOL in research of retinal neurodegenerative diseases, including AMD, diabetic Retinopathy, glaucoma. She has published 24 papers in this matter.
Master of biochemistry from Northeast Agricultural Univ. in China. 7 years’ experience in biomedical research, including drug screening with cells and rodents, diagnostic reagent development, published 3 papers